CTLA4 and hypophysitis: Hypophysitis linked to immune checkpoint toxicity is predominantly associated with the combined use of anti-CTLA4 and anti PD-1 therapies, reaching 10%, while its incidence is lower, at approximately 1–5%, with either monotherapy of the aforementioned inhibitors [15].